Boehringer

Bio similar Monoclonal Antibodies Global Market Report 2023: Featuring Biocon, Allergen, Ingelhiem, Pfizer & More - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 5, 2023
Health, Other Health, Social, Research, Hospira, Sport, Boehringer, Application, Politics, PEST, Growth, Novartis, Social technology, Investment, Celltrion, Fine chemical, Generic drug, Pfizer

The "Bio similar Monoclonal Antibodies Market, By Application, Type, Region: Global Forecast to 2028."

Key Points: 
  • The "Bio similar Monoclonal Antibodies Market, By Application, Type, Region: Global Forecast to 2028."
  • The report deals with all the driving factors, opportunities, and challenges with respect to the global Biosimilar Monoclonal Antibodies Market, which are helpful in identifying trends and key success factors for the industry.
  • Report further studies the market development status and future and Biosimilar Monoclonal Antibodies Market trend across the world.
  • Also, it splits Biosimilar Monoclonal Antibodies Market segmentation by component, deployment mode, application, vertical andregionto deep dive research and reveals market profile and prospects.

European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares

Retrieved on: 
Tuesday, December 13, 2022
Biotechnology, FDA, Pharmaceutical, Health, Consensus, Immune system, Delphi, Psoriasis, EC, Skin, Diagnosis, Hospital, Patient, GPP, European Commission, Boehringer, Quality of life, News, Infection, Boehringer Ingelheim, Flare, Pharmaceutical industry

Now with a specifically developed treatment, people living with GPP can be offered a new lease of life by effectively managing the impact of GPP flares.

Key Points: 
  • Now with a specifically developed treatment, people living with GPP can be offered a new lease of life by effectively managing the impact of GPP flares.
  • We are delighted to be able to bring this much needed treatment to patients with GPP, whose options were incredibly limited until this year.
  • Most patients at the outset of the trial had a moderate or severe pustulation of the skin.
  • For the full press release and link to Notes to Editors please click here:

Separating fact from opinion

Retrieved on: 
Monday, November 7, 2022
Review, FTC, Compliance, Disclosure, Barr Pharmaceuticals, Undue hardship, CID, Boehringer Ingelheim, Commission, DC circuit, Patent, Supreme, Risk, Private investigator, Dietary supplement, Insurance, Boehringer

Boehringer argued that these documents were protected opinion work product because they had been prepared at the request of its in-house counsel.

Key Points: 
  • Boehringer argued that these documents were protected opinion work product because they had been prepared at the request of its in-house counsel.
  • The district court agreed with Boehringer that the financial analyses contained protected opinion work product.
  • Circuit found that the district court had not correctly distinguished fact work product from the more highly protected opinion work product.
  • Specifically, the court held that counsels mere request for financial analyses during settlement discussions did not make those analyses opinion work product.

University of Tübingen and Boehringer Ingelheim Join Forces to Lead AI and Data Science R&D for New Medical Breakthroughs

Retrieved on: 
Thursday, October 20, 2022
Research, Technology, Biotechnology, University, Pharmaceutical, Health, Data Management, Science, Education, Artificial Intelligence, Fellows, Yale University, Digital Science, Health informatics, Method, Medicine, Growth, European environmental research and innovation policy, Boehringer, Human, Research, Program, Partnership, Cluster, University, Solution, Marketing, Industry, AI, Health, Computational biology, Boehringer Ingelheim, Ecosystem, Innovation, Machine learning, Artificial intelligence, Digital, Data science, Leadership, Medical device, Fine chemical, Science

University of Tbingen, a leading member of Cyber Valley , Europes largest Artificial Intelligence (AI) research consortium and Boehringer Ingelheim launch an AI and data science fellowship program for top talents from around the world.

Key Points: 
  • University of Tbingen, a leading member of Cyber Valley , Europes largest Artificial Intelligence (AI) research consortium and Boehringer Ingelheim launch an AI and data science fellowship program for top talents from around the world.
  • The partnership is founded in Boehringer Ingelheims and the University of Tbingens joint vision to harness the power of AI and data science to improve human and animal health.
  • They will benefit from the Universitys extensive expertise, rapid growth in AI and data science and highly reputed medical research.
  • With the newly established collaboration with the University of Tbingen Boehringer Ingelheim continues to foster AI and data science partnerships in multiple innovation spots in Europe, the USA and Asia.

Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements

Retrieved on: 
Wednesday, October 5, 2022
General Health, Health, Veterinary, News, Government, Growth, Animal, Vaccine, Boehringer, Farmer, Program, SE, Empowerment, Partnership, Software, Health, CEO, Boehringer Ingelheim, Intention, BI, Solution, Livestock, Agriculture

Boehringer Ingelheim announced today that Cowtribe is the first recipient of investment and non-financial support from the Boehringer Ingelheim Social Engagement (BI SE) initiative, a program which aims to close a critical financing gap for social businesses in vulnerable communities.

Key Points: 
  • Boehringer Ingelheim announced today that Cowtribe is the first recipient of investment and non-financial support from the Boehringer Ingelheim Social Engagement (BI SE) initiative, a program which aims to close a critical financing gap for social businesses in vulnerable communities.
  • Cowtribe, a leading last-mile veterinary delivery company from Ghana, leverages technology to help coordinate deliveries of veterinary vaccines and other animal health products to rural and underserved communities, where many farmers are dependent on just a few animals.
  • BI SE underlines Boehringer Ingelheims commitment to find innovative financing solutions with the intention to scale social impact.
  • We are delighted to grant the first investment of Boehringer Ingelheim Social Engagements to Cowtribe, said Ilka Wicke, Global Head of Making More Health at Boehringer Ingelheim.

Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)

Retrieved on: 
Wednesday, September 21, 2022
Fatty liver disease, Safety, COVID-19, Advertising, MD, Vomiting, NASH, Week, Overweight, GCG, Obesity, Intellectual property, Private Securities Litigation Reform Act, Metformin, Glucagon, Patient, BI, 2021 Essex County Council election, Abstract, Nasdaq, Liver, Science, Pharmacology, European Association for the Study of Diabetes, GCGR, Research, EASD, Boehringer Ingelheim, Association, Nausea, Boehringer, Incretin, T2D, Failure, Human, Fine chemical, Pharmaceutical industry, Vaccine, Glycated hemoglobin, Zealand Pharma

Preclinical data on BI 456906 will also be presented at the EASD annual meeting.

Key Points: 
  • Preclinical data on BI 456906 will also be presented at the EASD annual meeting.
  • BI 456906 is being developed by Boehringer Ingelheim and was co-invented with Zealand Pharma.
  • Most adverse events were reported during the dose-escalation phase of the trial, and therefore slower escalation schemes may mitigate the frequency.
  • Different doses of BI 456906 were escalated every 12 weeks to ensure that 10 weeks were spent on a maintenance dose.

DGAP-News: JDC Group AG: Ecclesia and JDC Group start cooperation

Retrieved on: 
Wednesday, August 3, 2022
Member, Insurance, ICRM, Industry, ISIN, DMS, CEO, BMW, Financial Oversight and Management Board for Puerto Rico, Nature, Fintech Valley Vizag, Technology, Commerce, Boehringer, Efficiency, JDC, Health, ESG, Contract, Public relations, Financial services, Financial adviser, Ecclesia, Lufthansa

The Ecclesia Group companies are expanding the digital service depth in the private insurance business through JDC's own broker management program iCRM.

Key Points: 
  • The Ecclesia Group companies are expanding the digital service depth in the private insurance business through JDC's own broker management program iCRM.
  • Through Ecclesia Gruppe Vorsorgemanagement GmbH as contracting partner with JDC Group AG, Ecclesia Group companies receive the full JDC platform as a broker management program for their private customer business.
  • "We are pleased to have won Ecclesia, the largest German broker for our platform solution," says Dr. Sebastian Grabmaier, CEO of JDC Group AG, commenting on the cooperation.
  • In addition, the Ecclesia Group has its own companies in six other European countries and operates in more than 170 countries worldwide via the ECCLESIA GLOBAL NETWORK.

DGAP-News: Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

Retrieved on: 
Wednesday, July 6, 2022
Diagnosis, Science, Patient, LinkedIn, Biotechnology, CEO, Frankfurt Stock Exchange, Research, Animal Health, SRL Diagnostics, EVO, Boehringer, Death, AMR, ESG, Industry, Disease, ISIN, Public health, MDAX, Infection, Neurology, Therapy, Drug discovery, Software, Euronext Paris, Health, News, Executive Office of the President of the United States, NASDAQ, DGAP, Boehringer Ingelheim, Board, Twitter, Injury, Diabetes, Security (finance), Fine chemical, Medical device, Pharmaceutical industry, Vaccine, Evotec

We are excited to launch Aurobac together with our partners at Boehringer Ingelheim and bioMrieux, to combine our complementary strengths.

Key Points: 
  • We are excited to launch Aurobac together with our partners at Boehringer Ingelheim and bioMrieux, to combine our complementary strengths.
  • We supply the most comprehensive integrated diagnostic solutions to support an appropriate use of antibiotics (antimicrobial stewardship), said Alexandre Mrieux, bioMrieux Chairman and CEO.
  • Our role within the joint venture is to develop and commercialize diagnostic tests, including Companion Diagnostics, which deliver rapid, reliable and actionable results.
  • bioMrieux has over 55 years of diagnostics expertise with more than 75% of its research and development budget focused on antimicrobial resistance.

Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

Retrieved on: 
Wednesday, July 6, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Diagnosis, Patient, CEO, Frankfurt Stock Exchange, Research, SRL Diagnostics, EVO, Boehringer, Death, AMR, Industry, ISIN, Public health, MDAX, Infection, Drug discovery, Executive Office of the President of the United States, NASDAQ, Boehringer Ingelheim, Board, Injury, Therapy, Diabetes, Fine chemical, Pharmaceutical industry, Vaccine, Evotec, EUR

The aspiration is to succeed in the fight against AMR, which is a major public health threat.

Key Points: 
  • The aspiration is to succeed in the fight against AMR, which is a major public health threat.
  • The rise of antibiotic-resistant infections also called antimicrobial resistance, or AMR is indeed a looming global crisis, said Michel Pairet, Head of Boehringer Ingelheims Innovation Unit and Member of the Board of Managing Directors.
  • We are excited to launch Aurobac together with our partners at Boehringer Ingelheim and bioMrieux, to combine our complementary strengths.
  • bioMrieux has over 55 years of diagnostics expertise with more than 75 percent of its research and development budget focused on antimicrobial resistance.

Boehringer Ingelheim signs Option to Acquire Trutino Biosciences

Retrieved on: 
Tuesday, June 14, 2022
Oncology, Health, Other Science, Clinical Trials, Science, Pharmaceutical, Biotechnology, Degenerative disease, Program, Research, Boehringer Ingelheim, MBA, Boehringer, CEO, Partnership, Cancer, Demand, Secondary research, Mentorship, Â, Patient, Doctor of Philosophy, Tumor microenvironment, Immune system, Cytokine, Potyvirus, Fine chemical, Vaccine

Boehringer Ingelheim today announced the signing of an option to acquire Trutino Biosciences Inc. (the Transaction), a San Diego-based biotech company.

Key Points: 
  • Boehringer Ingelheim today announced the signing of an option to acquire Trutino Biosciences Inc. (the Transaction), a San Diego-based biotech company.
  • Boehringer Ingelheim is excited to extend our partnership with Dr. Kim and his outstanding team at Trutino Biosciences.
  • The option fee and principal amount of the convertible note funded by Boehringer Ingelheim at the signing of the option will collectively fully finance Trutino Biosciences through the next major development milestones of Trutino Biosciences.
  • Boehringer Ingelheim and Trutino Biosciences were introduced in 2019 during one of Boehringer Ingelheims Grass Roots Innovation events in San Diego.